News

Case of PML

The pharmaceutical sponsor of Gilenya (fingolimod), Novartis, has this week reported one case of Progressive Multifocal Leukoencephalopathy (PML) in an individual currently being treated with Gilenya in Europe.

Novartis reports that over 119 000 people around the world have been treated with Gilenya.

This current case is complicated by the individual also receiving treatment for other concurrent illnesses in addition to MS, and it is not yet clear the extent to which Gilenya has contributed to this event.

Progressive multifocal leukoencephalopathy (PML) is a rare and potentially fatal viral brain infection characterised by progressive damage to the white matter of the brain. It is caused by the JC virus (JCV), which is present in about half of the general population, but only manifests in people whose immune system has been suppressed, including those on immunosuppressive medication. PML in people with MS is known to be a relatively rare safety risk of natalizumab treatment, with most cases of PML occurring after more than two years of natalizumab treatment.

This event should not be a cause for alarm in people currently taking Gilenya, and it is very important that people should not make any changes to their current medication regimen without first seeking medical advice. If you have any concerns about your current treatment plan, please speak to your neurologist.

Kiss Goodbye to MS Ambassadors

The inspiring Australians who are making a difference

Our Kiss Goodbye to MS ambassadors say thank you to the fantastic MS community by sharing their very own thank you letters.
remyelination MS

Is a naturally occurring molecule the key to remyelination?

MS researchers have investigated whether a naturally occurring molecule, which some DMTs mimic, has the capacity to promote myelin repair.

What us to keep you in the loop? Subscribe today!

  • Enter your details

Read More

Newsletter subscription

  • Enter your details

Case of PML